https://scholars.lib.ntu.edu.tw/handle/123456789/557876
標題: | Pertuzumab and trastuzumab as adjuvant treatment for HER2-positive early breast cancer: outcomes in Chinese patients in the APHINITY study | 作者: | Shao Z. Tseng L.-M. CHIUN-SHENG HUANG Pang D. Yang Y. Li W. Liao N. Geng C. Zhang Q. Xu B. Liu D. Kwong A. et al (continued in the appendix) |
關鍵字: | adjuvant; breast cancer; Chinese; HER2; pertuzumab | 公開日期: | 2021 | 出版社: | NLM (Medline) | 卷: | 51 | 期: | 3 | 起(迄)頁: | 345-353 | 來源出版物: | Japanese journal of clinical oncology | 摘要: | Background: The addition of pertuzumab to trastuzumab plus standard chemotherapy as adjuvant therapy following surgery significantly improved invasive disease-free survival (IDFS) in patients with HER2-positive early breast cancer in the multinational ran |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85102607614&doi=10.1093%2fjjco%2fhyaa216&partnerID=40&md5=004cc33a2d135f780c71dfc450691891 https://scholars.lib.ntu.edu.tw/handle/123456789/557876 |
ISSN: | 1465-3621 | DOI: | 10.1093/jjco/hyaa216 | SDG/關鍵字: | pertuzumab; placebo; trastuzumab; antineoplastic agent; epidermal growth factor receptor 2; monoclonal antibody; pertuzumab; trastuzumab; adjuvant chemotherapy; adult; aged; Article; China; Chinese; clinical outcome; clinical trial; demography; diarrhea; |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。